David Pompliano, formerly a vice president for antimicrobials at Merck & Co, has been appointed to the board of directors at Novacta Therapeutics Ltd, a privately-held UK biotechnology company.
Novacta is developing a class of small peptide molecules called lantibiotics. In addition to joining the Novacta board of directors, Dr Pompliano will chair the company's scientific advisory board.
At Merck, Dr Pompliano was responsible for the discovery and early development of antimicrobials. Prior to that, he was vice president and head of biology for the Microbial Musculoskeletal and Proliferative Diseases Center for Excellence in Drug Discovery at GlaxoSmithKline.
Copyright 2009 Evernow Publishing Ltd